Johnson & Johnson moves to buoy investors over paused Covid vaccine trial
Johnson & Johnson moves to buoy investors over paused Covid vaccine trial

Washington (AFP) – US pharmaceutical giant Johnson & Johnson sought Tuesday to reassure investors after its stock slumped on an announcement that it was pausing a Covid-19 vaccine trial over a sick participant.The company is one of several working on a vaccine, but on Monday it announced the unexplained illness, closing enrollment for the 60,000-patient trial while an independent patient safety committee is convened.The announcement sent shares tumbling 2.3 percent at the close of trading Tuesday, even as the company reported healthy third-quarter results, with sales growing 1.7 percent to $21…

Read More

HEDGE accordingly